{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:24:31Z","timestamp":1784697871695,"version":"3.55.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4109,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Focal biliary cirrhosis causes significant morbidity and mortality in cystic fibrosis (CF). Although the mechanisms of pathogenesis remain unclear, bile acids have been proposed as potential mediators of liver injury. This study examined bile acid composition in CF and assessed altered bile acid profiles to determine if they are associated with incidence and progression of liver injury in CF-associated liver disease (CFLD). Bile acid composition was determined by gas-liquid chromatography\/mass spectrometry in bile, urine, and serum samples from 30 children with CFLD, 15 children with CF but without liver disease (CFnoLD), and 43 controls. Liver biopsies from 29 CFLD subjects were assessed histologically by grading for fibrosis stage, inflammation, and disruption of the limiting plate. A significantly greater proportion of endogenous biliary ursodeoxycholic acid (UDCA) was demonstrated in CFnoLD subjects vs. both CFLD subjects and controls (2.4- and 2.2-fold, respectively; ANOVA, <jats:italic toggle=\"yes\">P<\/jats:italic> = .04), and a 3-4 fold elevation in endogenous serum UDCA concentration was observed in both CFLD subjects and CFnoLD subjects vs. controls (ANOVA, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). In CFLD, there were significant correlations between serum cholic acid and hepatic fibrosis, inflammation, and limiting plate disruption as well as the ratio of serum cholic acid\/chenodeoxycholic acid to hepatic fibrosis, inflammation, and limiting plate disruption. <jats:underline>In conclusion,<\/jats:underline> elevated endogenous UDCA in CFnoLD suggests a possible protective role against liver injury in these patients. The correlation between both cholic acid and cholic acid\/chenodeoxycholic acid levels with histological liver injury and fibrosis progression suggests a potential monitoring role for these bile acids in CFLD. (Hepatology 2004;39:1673-1682.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.20238","type":"journal-article","created":{"date-parts":[[2004,5,27]],"date-time":"2004-05-27T20:02:15Z","timestamp":1085688135000},"page":"1673-1682","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":56,"title":["Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis"],"prefix":"10.1097","volume":"39","author":[{"given":"Jeffery L.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lewindon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita C.","family":"Hoskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara N.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D. R.","family":"Setchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy C.","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross W.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"Ramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20241201","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/j.1536-4801.1982.tb08374.x","article-title":"Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts.","volume":"1","author":"Roy","year":"1982","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R2-27-20241201","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-2008-1040717","article-title":"Cystic fibrosis: its influence on the liver, biliary tree, and bile salt metabolism.","volume":"2","author":"Isenberg","year":"1982","journal-title":"Semin Liver Dis"},{"key":"R3-27-20241201","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2007-1007159","article-title":"Liver and biliary problems in cystic fibrosis.","volume":"18","author":"Colombo","year":"1998","journal-title":"Semin Liver Dis"},{"key":"R4-27-20241201","first-page":"340","article-title":"Liver disease in children with cystic fibrosis.","volume":"2","author":"Diwakar","year":"2001","journal-title":"Paediatr Respir Rev"},{"key":"R5-27-20241201","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM198802113180602","article-title":"Liver disease and common-bile-duct stenosis in cystic fibrosis.","volume":"318","author":"Gaskin","year":"1988","journal-title":"N Engl J Med"},{"key":"R6-27-20241201","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3476(94)70361-2","article-title":"Analysis of risk factors for the development of liver disease associated with cystic fibrosis.","volume":"124","author":"Colombo","year":"1994","journal-title":"J Pediatr"},{"key":"R7-27-20241201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/adc.81.2.129","article-title":"The evolution of liver disease in cystic fibrosis.","volume":"81","author":"Ling","year":"1999","journal-title":"Arch Dis Child"},{"key":"R8-27-20241201","first-page":"1437","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245: 1066-1073erratum: S","volume":"245","author":"Riordan","year":"1989","journal-title":"cience"},{"key":"R9-27-20241201","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/hep.1840160412","article-title":"Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.","volume":"16","author":"Colombo","year":"1992","journal-title":"HEPATOLOGY"},{"key":"R10-27-20241201","first-page":"198","article-title":"Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.","volume":"19","author":"Merli","year":"1994","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R11-27-20241201","first-page":"1484","article-title":"Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.","volume":"23","author":"Colombo","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R12-27-20241201","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00365529709007686","article-title":"Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up.","volume":"32","author":"van de Meeberg","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"R13-27-20241201","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/106002809703100909","article-title":"Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.","volume":"31","author":"Scher","year":"1997","journal-title":"Ann Pharmacother"},{"key":"R14-27-20241201","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hep.510250303","article-title":"Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.","volume":"25","author":"Jacquemin","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R15-27-20241201","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hep.510270126","article-title":"A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.","volume":"27","author":"Lindblad","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R16-27-20241201","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0168-8278(99)80347-X","article-title":"Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.","volume":"31","author":"Colombo","year":"1999","journal-title":"J Hepatol"},{"key":"R17-27-20241201","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00004836-200104000-00009","article-title":"Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.","volume":"32","author":"Nousia-Arvanitakis","year":"2001","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"R18-27-20241201","first-page":"CD000222","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease.","author":"Cheng","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-27-20241201","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1203\/00006450-197005000-00005","article-title":"Bile acid concentrations in serum during infancy and childhood.","volume":"4","author":"Sandberg","year":"1970","journal-title":"Pediatr Res"},{"key":"R20-27-20241201","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM197311082891903","article-title":"Malabsorption of bile acids in children with cystic fibrosis.","volume":"289","author":"Weber","year":"1973","journal-title":"N Engl J Med"},{"key":"R21-27-20241201","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/00365528009181435","article-title":"Urinary bile acid excretion in correlation to liver histopathology in cystic fibrosis.","volume":"15","author":"Arborgh","year":"1980","journal-title":"Scand J Gastroenterol"},{"key":"R22-27-20241201","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/00365528509091668","article-title":"Fasting serum bile acid levels in relation to liver histopathology in cystic fibrosis.","volume":"20","author":"Strandvik","year":"1985","journal-title":"Scand J Gastroenterol"},{"key":"R23-27-20241201","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0009-8981(85)90313-4","article-title":"Serum bile acid composition in patients with cystic fibrosis.","volume":"151","author":"Setchell","year":"1985","journal-title":"Clin Chim Acta"},{"key":"R24-27-20241201","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.1840120221","article-title":"Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.","volume":"12","author":"Nakagawa","year":"1990","journal-title":"HEPATOLOGY"},{"key":"R25-27-20241201","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0002-9440(10)61117-0","article-title":"The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease.","volume":"160","author":"Lewindon","year":"2002","journal-title":"Am J Pathol"},{"key":"R26-27-20241201","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment.","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"R27-27-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-0801(199601)10:1<1::AID-BMC536>3.0.CO;2-3","article-title":"Performance characteristics of reversed-phase bonded silica cartridges for serum bile acid extraction.","volume":"10","author":"Rodrigues","year":"1996","journal-title":"Biomed Chromatogr"},{"key":"R28-27-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-8981(83)90070-0","article-title":"Serum bile acid analysis.","volume":"127","author":"Setchell","year":"1983","journal-title":"Clin Chim Acta"},{"key":"R29-27-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(94)00073-C","article-title":"Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.","volume":"66","author":"Poupon","year":"1995","journal-title":"Pharmacol Ther"},{"key":"R30-27-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365529409103618","article-title":"Pharmacology of ursodeoxycholic acid, an enterohepatic drug.","volume":"204","author":"Hofmann","year":"1994","journal-title":"Scand J Gastroenterol Suppl"},{"key":"R31-27-20241201","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.1840170308","article-title":"Formation of 7 alpha- and 7 beta-hydroxylated bile acid precursors from 27-hydroxycholesterol in human liver microsomes and mitochondria.","volume":"17","author":"Shoda","year":"1993","journal-title":"HEPATOLOGY"},{"key":"R32-27-20241201","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2002.36591","article-title":"The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.","volume":"123","author":"Byrne","year":"2002","journal-title":"Gastroenterology"},{"key":"R33-27-20241201","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1053\/gast.2002.36587","article-title":"Functional expression of the canalicular bile salt export pump of human liver.","volume":"123","author":"Noe","year":"2002","journal-title":"Gastroenterology"},{"key":"R34-27-20241201","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/gast.2001.25542","article-title":"Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.","volume":"121","author":"Fickert","year":"2001","journal-title":"Gastroenterology"},{"key":"R35-27-20241201","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/jhep.2002.34939","article-title":"Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP and preservation of BSEP activities.","volume":"36","author":"Paolini","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R36-27-20241201","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.","volume":"36","author":"Paumgartner","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R37-27-20241201","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1365-2036.1999.00596.x","article-title":"Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.","volume":"13","author":"Trauner","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-27-20241201","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/gut.26.11.1246","article-title":"Conjugated bile acids in serum and secretions in response to cholecystokininsecretin stimulation in children with cystic fibrosis.","volume":"26","author":"Robb","year":"1985","journal-title":"Gut"},{"key":"R39-27-20241201","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/0016-5085(95)90407-7","article-title":"Ursodeoxycholate increases cytosolic calcium concentration and activates Cl- currents in a biliary cell line.","volume":"109","author":"Shimokura","year":"1995","journal-title":"Gastroenterology"},{"key":"R40-27-20241201","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0016-5085(93)90735-U","article-title":"Abnormal expression of anion exchanger genes in primary biliary cirrhosis.","volume":"105","author":"Prieto","year":"1993","journal-title":"Gastroenterology"},{"key":"R41-27-20241201","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/gut.34.8.1137","article-title":"Intestinal bile acid malabsorption in cystic fibrosis.","volume":"34","author":"OBrien","year":"1993","journal-title":"Gut"},{"key":"R42-27-20241201","first-page":"1224","article-title":"Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats.","volume":"18","author":"Azer","year":"1993","journal-title":"HEPATOLOGY"},{"key":"R43-27-20241201","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1440-1746.1996.tb00064.x","article-title":"Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease.","volume":"11","author":"Azer","year":"1996","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20238","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200406000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:14:45Z","timestamp":1733055285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200406000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20238","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}